Approximately 1.4 million people in the United States have been affected by inflammatory bowel disease (IBD), and the number is growing. The Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center at Mount Sinai is conducting research to understand t...

People living with Crohn's disease (CD) experience psychological and emotional symptoms, in addition to known chronic and disabling physical symptoms, which prevent them from living their life to the fullest (flourishing). Depression and anxiety are experienced by 30...

The Sweat Sensor Study at Mount Sinai aims to measure and monitor markers of inflammation and the immune system, such as C-reactive protein and calprotectin, continuously in the sweat using a wearable sweat sensing device. Our hope is that this wearable device will even...

The PLANET Study aims to determine the impact of microplastics on intestinal inflammation and gut microbiome in order to understand the role of this pollutant on the risk of developing inflammatory bowel disease (IBD) as well as other diseases. With this information,...

Delivery of healthcare has been traditionally limited to in-person visits or hospitalizations, while patients spend the majority of their time at home or work. Digital Medicine (e.g. apps, remote monitoring, telemedicine, patient reported outcomes) has the potenti...

Crohn's disease (CD) is the major form of inflammatory bowel disease (IBD) affecting adults. It is a life-long disease characterized by chronic and relapsing inflammation of the gastrointestinal tract. CD has multiple clinical phenotypes and disease severities that d...

TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical practice. TARGET-IBD will create a research registry of patients with IBD within academic ...